M.D. Sass LLC Raises Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

M.D. Sass LLC lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 22.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 391,824 shares of the medical research company’s stock after acquiring an additional 70,652 shares during the quarter. Charles River Laboratories International accounts for approximately 5.4% of M.D. Sass LLC’s portfolio, making the stock its 2nd largest position. M.D. Sass LLC’s holdings in Charles River Laboratories International were worth $72,331,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in Charles River Laboratories International during the third quarter worth about $601,000. JPMorgan Chase & Co. increased its position in shares of Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after purchasing an additional 85,759 shares during the last quarter. State Street Corp raised its holdings in shares of Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after buying an additional 41,421 shares in the last quarter. Janus Henderson Group PLC lifted its position in Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock worth $9,064,000 after buying an additional 3,268 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in Charles River Laboratories International in the third quarter worth approximately $966,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $190.00 to $170.00 in a report on Friday. UBS Group reissued a “neutral” rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Robert W. Baird reduced their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their target price for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. Finally, Barclays reduced their price target on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Stock Up 0.0 %

Shares of Charles River Laboratories International stock opened at $167.29 on Tuesday. The company’s fifty day simple moving average is $165.66 and its two-hundred day simple moving average is $183.49. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $273.57. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a market cap of $8.55 billion, a P/E ratio of 1,115.28, a PEG ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same period last year, the business posted $2.46 earnings per share. Charles River Laboratories International’s quarterly revenue was down 1.1% compared to the same quarter last year. Research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).